Intestinal Candidiasis: Symptoms, Causes, and Treatment

Intestinal candidiasis is an overgrowth of Candida yeast in the gut, producing symptoms like bloating, abdominal pain, and altered bowel habits that overlap heavily with irritable bowel syndrome and other digestive conditions. Candida species live in the intestines of most healthy people, so the problem is not the presence of the fungus itself but a shift in the balance between it and the bacteria that normally keep it in check. That distinction makes the condition genuinely tricky to diagnose, controversial in some medical circles, and surprisingly dependent on factors you might not expect.

Candida Is Already in Your Gut

Before thinking about overgrowth, it helps to know how common Candida is under normal circumstances. An analysis of stool samples from the Human Microbiome Project found Candida albicans in roughly 81% of healthy participants.¹ The fungal species capable of truly colonizing the gut, rather than just passing through with food, are limited to a small group dominated by Candida yeasts.² In other words, carrying Candida is not a disease. It is the default state of the human intestine.

What prevents that resident Candida from causing problems is largely the bacterial community around it. Certain bacterial families, especially those that produce short-chain fatty acids like butyrate and acetate, appear to suppress Candida growth directly. When researchers modeled the human colon environment, they found that the bacterial groups most strongly associated with keeping Candida albicans levels low were butyrate- and acetate-producing species in the Lachnospiraceae family, along with Bifidobacterium and Bacteroides.³ The lactic acid bacteria of the gut also play a vital role in preventing fungal invasion.⁴ When those bacterial populations are disrupted, Candida has room to expand.

What Triggers Overgrowth

Several well-established factors can tip the balance toward Candida overgrowth. Some are medical, some are dietary, and some are things people take every day without much thought.

Antibiotics

Broad-spectrum antibiotics are the most clearly documented trigger. They kill off the bacteria that compete with Candida for space and resources, while leaving the fungus untouched. In mice treated with cefoperazone, a common broad-spectrum antibiotic, Candida albicans loads in the gut jumped by roughly a thousandfold compared to untreated animals, and the levels of short-chain fatty acids in the cecum dropped significantly at the same time.⁵ The link between lost bacterial diversity, falling short-chain fatty acid production, and rising Candida is one of the more consistent findings in this field. Infants on long-term antibiotics also show elevated urinary markers of Candida activity, suggesting the same mechanism applies in humans.⁶

Proton Pump Inhibitors

Acid-suppressing medications, particularly proton pump inhibitors, are an underappreciated contributor. PPIs reduce stomach acidity, which may allow ingested fungi to survive passage into the small intestine more easily. In patients with gastroesophageal reflux disease, those taking PPIs showed significantly increased Candida colonization of the gastric mucosa compared to untreated patients, with Candida identified as a biomarker distinguishing PPI users from non-users.⁷ A separate study found that PPI use and gut dysmotility were each independent risk factors for small intestinal fungal or bacterial overgrowth.⁸ This is worth knowing because millions of people take PPIs chronically for heartburn, often without realizing they may be shifting their gut fungal balance.

Diabetes and Immune Suppression

Diabetes mellitus, particularly when blood sugar is poorly controlled, increases susceptibility to Candida infections throughout the body, including the gut. The metabolic disorder has an immunosuppressive effect that makes it harder for the body to keep fungal populations in check.⁹ More broadly, any condition or medication that weakens the immune system, including HIV infection, organ transplant medications, and chemotherapy, creates conditions favorable for Candida expansion. When Candida albicans shifts from its normal yeast form to a filamentous hyphal form, it can damage the intestinal lining and, in severely immunocompromised people, cross the gut barrier entirely.¹⁰ That translocation is what can lead to life-threatening bloodstream infections, though it is rare in people with intact immune systems.

Diet

Western-style diets high in refined sugar and fat and low in vegetable fiber have been linked to gut dysbiosis and Candida overgrowth.¹¹ The reasoning tracks with everything above: a diet poor in fiber starves the bacteria that produce short-chain fatty acids, which are the very compounds that suppress Candida growth. More fiber means more bacterial fermentation, more short-chain fatty acids, and a less hospitable environment for fungal expansion.

Symptoms and the Overlap Problem

The symptoms most commonly attributed to intestinal candidiasis include bloating, abdominal pain, gas, diarrhea or loose stools, and sometimes fatigue and brain fog. The trouble is that this list reads almost identically to irritable bowel syndrome, small intestinal bacterial overgrowth, food intolerances, and a handful of other functional gut disorders. That overlap is a real obstacle, both for patients trying to figure out what is wrong and for doctors trying to distinguish one condition from another.

Research has confirmed that the connection between gut Candida and IBS-like symptoms is not imaginary. In patients with diarrhea-predominant IBS, Candida albicans was more abundant than in healthy controls, and Candida levels correlated positively with the severity of bloating and anxiety.¹² Separately, IBS patients overall showed a shift toward higher Candida albicans in their gut fungal communities, though this shift appeared in both those with heightened pain sensitivity and those without, making it unclear whether Candida is driving pain or simply flourishing in an already disturbed gut.¹³

There is also a substantial overlap between small intestinal fungal overgrowth and small intestinal bacterial overgrowth, with about a third of SIBO patients also eventually diagnosed with fungal overgrowth.¹⁴ This means that if you have been treated for bacterial overgrowth without full resolution of symptoms, persistent fungal overgrowth could be part of the picture.

The idea of a broader “chronic candidiasis syndrome” that includes fatigue, cognitive symptoms, and widespread malaise has been debated since at least the 1990s. It was noted early on that patients with putative chronic intestinal candidiasis share many symptoms with chronic fatigue syndrome, minus the flu-like features.¹⁵ The concept remains somewhat polarizing in mainstream medicine. Some clinicians consider systemic symptoms plausible through mechanisms like immune activation and metabolite production; others regard the extraintestinal claims as unproven. What is less controversial is that Candida overgrowth in the gut can alter host biology beyond the digestive tract. In a mouse model, colonization with Candida albicans disrupted endocannabinoid signaling and altered stress hormone responses, suggesting a genuine gut-brain pathway through which intestinal fungi could influence mood and cognition.¹⁶

How Intestinal Candidiasis Gets Diagnosed

Diagnosis is one of the weakest links in managing this condition. There is no universally accepted, simple test for “too much Candida in the gut.” Since Candida is a normal resident, merely finding it in a stool sample does not prove disease. Both culture-based methods and DNA-sequencing approaches are used in research settings, but neither has an established clinical cutoff that reliably separates normal colonization from pathological overgrowth.¹⁷

For suspected small intestinal fungal overgrowth specifically, aspiration of fluid from the small intestine during an upper endoscopy, followed by fungal culture, is considered the most direct test. A fungal count above a certain threshold in the aspirate is used to make the diagnosis. But this requires an invasive procedure and is not available in most primary care settings, which means many cases go undiagnosed or are treated empirically based on symptoms and risk factors.

One experimental biomarker that has shown promise, at least in newborns and infants, is the urinary D-arabinitol to L-arabinitol ratio. D-arabinitol is a metabolite produced by most disease-causing Candida species, and elevated ratios have been used to identify invasive candidiasis in neonates, sometimes catching infections that blood cultures missed.¹⁸ This approach remains largely a research tool and is not widely available for adults with suspected intestinal overgrowth, but it illustrates the direction the field is moving: toward metabolic markers that reflect what the fungus is actually doing, rather than just whether it is present.

Antifungal Treatment

When intestinal candidiasis is suspected or confirmed, antifungal drugs are the primary treatment. The two most commonly used are nystatin and fluconazole, and they work in fundamentally different ways.

Nystatin is a topical antifungal that is not absorbed into the bloodstream. When taken orally, it passes through the gut and acts directly on Candida in the intestinal lumen. This makes it relatively safe with few systemic side effects, and it is often the first-line choice for non-invasive gut overgrowth. In a trial of liver transplant recipients, nystatin reduced Candida colonization and superficial infections, though it was less effective than fluconazole: about 53% of the nystatin group developed Candida colonization compared to 25% of the fluconazole group.¹⁹

Fluconazole is a systemic azole antifungal, meaning it is absorbed into the blood and distributed throughout the body. It tends to be more effective at clearing Candida, but it also carries more potential for drug interactions and liver effects, especially with long-term use. For intestinal overgrowth in otherwise healthy people, the choice between nystatin and fluconazole often comes down to severity and how confident the clinician is in the diagnosis.

A different class of antifungals, the echinocandins (like caspofungin), are used primarily for serious systemic Candida infections. They are given intravenously and are not standard treatment for gut overgrowth. Research has highlighted a concerning limitation: in a mouse model of Candida glabrata colonization, therapeutic doses of caspofungin failed to reduce intestinal fungal loads and did not prevent organ breakthrough, while also promoting resistance.²⁰ The gut appears to serve as a reservoir where Candida can develop drug resistance, which has implications for how aggressively and for how long antifungals should be used.

Why Biofilms Complicate Things

One reason intestinal Candida can be stubborn despite antifungal treatment is its ability to form biofilms. A biofilm is essentially a community of fungal cells embedded in a self-produced sticky matrix that adheres to surfaces, including the intestinal lining. This matrix physically shields the Candida cells from both antifungal drugs and the immune system. Research has shown that the matrix component beta-1,3-glucan is particularly responsible for the drug-resistant properties of these biofilms, influencing genes that make the structure more impervious to treatment.²¹

Biofilm formation helps explain a common clinical frustration: symptoms improve during antifungal treatment but return after stopping it. The free-floating Candida cells are killed, but the biofilm-protected cells survive and repopulate the gut once the drug pressure is removed. This is part of why many practitioners combine antifungal medication with dietary and probiotic strategies aimed at making the gut environment less friendly to Candida long term, rather than relying on drugs alone.

Dietary Changes and Probiotics

The evidence for dietary modification as a complement to antifungal treatment is still developing, but what exists is encouraging. In a pilot study, patients treated with nystatin who also followed a recommended anti-Candida diet had significantly better outcomes than those treated with nystatin alone. At the three-month follow-up stool exam, 85% of the diet-plus-nystatin group were free of overgrowth, compared to about 43% in the nystatin-only group.²² That is a striking difference for a dietary intervention, though the study was small and pilot-scale.

The logic behind anti-Candida diets centers on reducing the refined carbohydrates and sugars that feed yeast while increasing the fiber that feeds the short-chain-fatty-acid-producing bacteria that suppress it. A recent study in fibromyalgia patients tested an extreme version of this approach: a carbohydrate-free diet for 45 days. The result was a marked reduction in fungal abundance (particularly Ascomycota, the phylum that includes Candida) and an increase in butyrate-producing bacteria like Faecalibacterium and Roseburia. These changes partially reversed once the participants transitioned to a less restrictive low-glycemic diet.²³ The practical takeaway is that sugar restriction seems to genuinely reduce gut Candida levels, but the effect may not be permanent without sustained dietary changes.

Probiotics are widely recommended alongside antifungal treatment, and there is a reasonable biological basis for this. Probiotic organisms can physically compete with Candida for space on the gut lining, aggregate pathogenic cells to reduce their ability to adhere, and produce metabolites like short-chain fatty acids that inhibit Candida’s transition from harmless yeast to invasive filamentous forms.²⁴ However, the evidence is not uniformly positive. In a mouse study testing Saccharomyces boulardii, one of the most commonly recommended probiotic yeasts for gut health, oral administration did not prevent subsequent Candida albicans colonization.²⁵ So while probiotics as a category have plausible mechanisms against Candida, not every popular probiotic strain delivers on that promise. Bacterial strains, particularly Lactobacillus species, may be more directly relevant to keeping Candida in check than yeast-based probiotics.

Oregano Oil and Other Natural Antifungals

You will find oregano oil mentioned in almost every alternative health discussion of intestinal candidiasis, and in this case there is lab research behind the recommendation. Oregano oil, and its active component carvacrol, completely inhibited Candida albicans growth in culture at relatively low concentrations and blocked both germination and the transition to the invasive filamentous form. In a mouse systemic candidiasis model, daily oregano oil administration resulted in 80% survival over 30 days, compared to complete mortality in the control group.²⁶

The major caveat is that lab and mouse results do not automatically translate to human gut conditions. The concentration of oregano oil that reaches the intestine after oral supplementation, how long it persists, and whether it harms beneficial bacteria along with Candida are all open questions. Other plant-derived compounds like caprylic acid, berberine, and garlic extract have in vitro antifungal activity as well, but controlled human trials remain scarce. These supplements are probably best viewed as potential adjuncts to conventional treatment and dietary changes, not replacements for them.

When Gut Fungi Affect Inflammation and Immunity

The relationship between intestinal fungi and inflammatory bowel conditions is an area of active research with findings that are interesting but incomplete. Fungal dysbiosis involving Candida and other species has been associated with inflammatory bowel disease and metabolic disorders, though whether the fungal shifts are a cause, a consequence, or simply a bystander of inflammation is still being sorted out.²⁷ What is clear is that the gut’s fungal community is not a passive passenger. It interacts with the immune system, influences bacterial neighbors, and can alter host biology in ways that extend well beyond digestion. The practical meaning for someone dealing with stubborn gut symptoms is that addressing the fungal component, through a combination of reducing risk factors, targeted antifungals when indicated, and sustained dietary support for beneficial bacteria, may be a piece of the puzzle that standard gastroenterology workups miss.